Table 1 Sensitivity of TIS A549 lung cancer cells to BH3 mimetics.

From: Mitochondrial priming and response to BH3 mimetics in “one-two punch” senogenic-senolytic strategies

 

IC50 (μmol/L) ± SD

ABT-263/navitoclax

A1331852

ABT-199/venetoclax

S63845

Proliferative (untreated)

8.69 ± 1.23 (1)

>20 (1)

19.28 ± 0.62 (1)

>20 (1)

Palbociclib TIS

6.39 ± 1.14 (1.4)

1.95 ± 1.15 (>10)

>20 (<1)

>20 (1)

Doxorubicin TIS

3.25 ± 0.31 (2.7)

1.31 ± 0.12 (>15)

>20 (<1)

>20 (1)

Alisertib TIS

0.89 ± 0.23 (9.8)

0.06 ± 0.02 (>300)

>20 (<1)

>20 (1)

Bleomycin TIS

0.22 ± 0.03 (39.5)

2.50E-03 ± 0.001 (>8000)

17.07 ± 1.20 (1.1)

>20 (1)

  1. Proliferative and TIS A549 cells were incubated with serial dilutions of BH3 mimetics. The IC50 values were determined as the μmol/L concentrations of BH3 mimetics required to decrease cell viability by 50%. Numbers in parentheses are the senolytic indexes (SI) obtained by dividing the IC50 values of BH3 mimetics in proliferative A549 cells by those obtained in TIS A549 cells. Data represent the mean ± S.D. of 3 or more experiments.
Back to article page